Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Septerna, Inc. - Common Stock (NQ:SEPN)

36.32 +2.85 (+8.52%)
Streaming Delayed Price Updated: 1:45 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 545,261
Open 34.46
Bid (Size) 36.00 (400)
Ask (Size) 36.39 (100)
Prev. Close 33.47
Today's Range 34.43 - 37.75
52wk Range 10.62 - 37.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? ↗
Septerna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? ↗
This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+29.8%
+29.8%
1 Month
+19.4%
+19.4%
3 Month
+46.6%
+46.6%
6 Month
+35.6%
+35.6%
1 Year
+234.7%
+234.7%

More News

Read More
News headline image
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
From Septerna, Inc.
Via Business Wire
News headline image
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Present at Bank of America Securities Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Present at TD Cowen 46th Annual Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Participate in 8th Annual Evercore Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
News headline image
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead ↗
Via MarketBeat
Topics World Trade
News headline image
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
From Septerna, Inc.
Via GlobeNewswire
News headline image
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
News headline image
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗
Via Benzinga
News headline image
This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
Via Benzinga
News headline image
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga
News headline image
The Analyst Verdict: Septerna In The Eyes Of 4 Experts ↗
Via Benzinga

Frequently Asked Questions

Is Septerna, Inc. - Common Stock publicly traded?
Yes, Septerna, Inc. - Common Stock is publicly traded.
What exchange does Septerna, Inc. - Common Stock trade on?
Septerna, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Septerna, Inc. - Common Stock?
The ticker symbol for Septerna, Inc. - Common Stock is SEPN on the Nasdaq Stock Market
What is the current price of Septerna, Inc. - Common Stock?
The current price of Septerna, Inc. - Common Stock is 36.32
When was Septerna, Inc. - Common Stock last traded?
The last trade of Septerna, Inc. - Common Stock was at 07/07/26 01:45 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.